Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
Journal: 2022/January - Frontiers in Pharmacology
Abstract:
GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO3 -. All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future.
Keywords: GPBAR1; GPBAR1 agonists; bile acids; cholestasis; inflammation; liver disease.
Relations:
Content
Diseases
(3)
Conditions
(1)
Organisms
(1)
Processes
(2)
Anatomy
(4)
Similar articles
Articles by the same authors
Discussion board

Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases

State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China,
Hospital of Chengdu University of Traditional Chinese Medicine, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China,
Department of Pharmacy, The Fifth Medical Center of PLA General Hospital, Beijing, China,
Edited by:Feng Li, Baylor College of Medicine, United States
Reviewed by:Stefano Fiorucci, University of Perugia, Italy

Wendong Huang, Beckman Research Institute, United States

*Correspondence: Xiao Ma, moc.361@oaixamybot; Yanling Zhao, moc.621@5582lyoahz
This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Edited by:Feng Li, Baylor College of Medicine, United StatesReviewed by:Stefano Fiorucci, University of Perugia, Italy

Wendong Huang, Beckman Research Institute, United States

This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology
Received 2021 Oct 30; Accepted 2021 Dec 23.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Abstract

GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO3. All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future.

Keywords: GPBAR1, bile acids, cholestasis, liver disease, inflammation, GPBAR1 agonists
Abstract

An external file that holds a picture, illustration, etc.
Object name is fphar-12-805269-fx1.jpg

The role of GPBAR1 in cholestatic diseases.

EC50 values (μM) were calculated from at least three independent experiments; h in the table represents the activity of GPBAR1 in human, and m represents mouse; d represents dual agonists.

Acknowledgments

The authors would like to thank the reviewers and the authors of all references.

Acknowledgments
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.